薬理と治療

Abstract

Objective　This study investigated the effects of supplemental intake of live yeast（Saccharomyces cerevisiae NK–1）on postprandial blood glucose levels and carbohydrate metabolism in humans. Methods　Two randomized, double–blind, placebo–controlled, crossover trials were conducted. Both used the same test food containing either 1.61 g of Saccharomyces cerevisiae NK–1 or an equivalent amount of lactose for the placebo. 　　Continuous intake trial: 30 participants（14 males, 16 females）consumed for two weeks, followed by Trelan tests and measurements of 13CO2 in the expired gas post–ingestion of 13C–labeled glucose. This intake phase was interspersed with a three–week washout period. 　　Single intake trial: 24 participants（8 males, 16 females）underwent a glucose tolerance test using rice, interspersed with one week washout period. Results　Continuous intake trial: The amount of 13CO2 in the expired gas over a 75–minute period post–ingestion of 13C–labeled glucose was significantly higher in the test group compared to the placebo group. In the glucose tolerance test using Trelan, there was no significant difference between the groups in blood glucose levels. 　　Single intake trial: In the glucose tolerance test using rice, the test group showed a signifi-cant decrease in blood glucose Area Under Curve（AUC）, blood glucose levels at 60 minutes, insulin levels at 60 minutes, and blood glucose Cmax in comparison to the placebo group. 　　Safety analysis: There were no adverse events in the single intake trial. Mild adverse events in the continuous intake trial were not related to the test food. Conclusion　Intake of live yeast significantly suppressed the elevation of postprandial blood glucose levels. This effect is suggested to be due to carbohydrate metabolism mediated by live yeast, as indicated by the analysis of 13CO2 in the expired gas following the ingestion of 13C–labeled glucose. Furthermore, Consumption of the test foods was safe.（UMIN ID：UMIN000043531，UMIN000046921）（Jpn Pharmacol Ther 2024；52：189‒99）